Efficacy and Safety of an Oral Growth Hormone Drug in the Treatment of Fibromyalgia

NCT00116129 | Completed Phase 2

• 2 other identifiers: MK-0677/FMIND 71,596
• Study Type: interventional
• Target: 64
• Locations: 1 country
• Sites: 1

Brief Summary

This is a 24-week, randomized, double-blind, placebo-controlled, trial to evaluate the safety, tolerability and efficacy of an orally administered growth hormone stimulating drug, (code named MK-0677) in the treatment of female subjects with primary fibromyalgia. The basis for this study is the observation that many fibromyalgia patients are growth hormone deficient; an earlier study of injectable growth hormone had shown benefit in this population of fibromyalgia patients.

Conditions

Fibromyalgia

Keywords

Fibromyalgia; Treatment; Growth hormone; IGF-1; MK-0677; Oral growth hormone secretagogue

Outcome Measures

Primary Outcomes (2)

• MK-0677 25 mg is superior to placebo in reducing symptoms of fibromyalgia, as assessed by the Fibromyalgia Impact Questionnaire (FIQ) over a 24-week treatment period

  Six months

• MK-0677 25 mg is generally safe and well tolerated in subjects with fibromyalgia

  Six months

Secondary Outcomes (2)

• MK-0677 25 mg is superior to placebo in improving the subjects' global perception of change in fibromyalgia symptoms, as assessed by the Subjects' Global Impression of Change Questionnaire (PGIC)

  Six months

• MK-0677 25 mg is superior to placebo in improving the subjects' quality of life, as assessed by the Quality of Life Questionnaire (QOL)

  Six months

Study Arms (1)

Placebo

PLACEBO COMPARATOR

Placebo

Drug: Ibutamoren Mesylate (MK-0677)

Interventions

Ibutamoren Mesylate (MK-0677) DRUG

Ibutamoren Mesylate 25 mg/day

Placebo

Eligibility Criteria

• Age: 30 Years - 65 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects will all be female primary fibromyalgia subjects who are 30 to 65 years of age, inclusive, and have a low age adjusted serum IGF-1 level.
• All subjects will fulfill a diagnosis of fibromyalgia according to the classification criteria of the American College of Rheumatology (ACR).
• All subjects will have an initial Fibromyalgia Impact Questionnaire (FIQ) score ≥ 40.
• If subject is of childbearing potential and sexually active, she agrees to use effective barrier or appropriate oral contraception during the study. Subjects who are taking oral contraceptives must have done so for at least 2 months prior to entering the study.
• Subject is not pregnant and is not nursing.
• Patient has a normal screening breast exam. If screening breast exam is abnormal, but not suggestive of breast cancer, the patient must have had a normal mammogram within the last 6 months.
• Subject has a normal screening stool hemoccult. If the screening stool hemoccult is abnormal, but likely due to hemorrhoids, the subject must have had a normal sigmoidoscopy within the last 2 years.
• Subject is willing to discontinue using grapefruit juice for duration of study.
• Subject is willing to be followed by telephone contact for 3 months after she has discontinued study and completed and returned the Fibromyalgia Impact Questionnaire, Patient Global Change score, Quality of Life score, Brief Pain Inventory and Beck Depression Questionnaire.

You may not qualify if:

• Subject has an-ongoing, unresolved disability litigation.
• Subject has diabetes or a significantly elevated random glucose at the Screening visit.
• Subject has a current or past history of cardiovascular, pulmonary, neurological, endocrine or renal disease that would preclude involvement in an exercise program (specifically hypertension, a myocardial infarction within the last 6 months, chronic obstructive pulmonary disease \[COPD\], asthma, untreated hypothyroidism, severe depression with suicide risk, previous pituitary disease or surgery).
• Subject has a history of angina or congestive heart failure with symptoms that occur at rest.
• Subject has a history or current evidence of a psychotic disorder (e.g. schizophrenia), bipolar disorder or major depression, or substance abuse by DSM-IV criteria; severe depression, as evidenced by a Beck Depression score of ≥ 30.
• Subject has history of neurological disorder other than fibromyalgia (e.g. epilepsy, stroke, neuropathy, neuropathic pain).
• Subject has ongoing symptoms of carpal tunnel syndrome.
• Subject has any other significant pain state, i.e. subject must have primary fibromyalgia.
• Subject has a history of hepatitis or liver disease that has been active within the past 12 weeks.
• Subject has cancer or a history of cancer within the past 2 years, or a history of cancer of more than 2 years ago and deemed to not be cured, or subject has ANY history of breast cancer. (NOTE: Subjects with a history of basal cell or squamous cell carcinoma of the skin treated more than 1 year ago and with no evidence of recurrence may participate.)
• Subject has abnormal thyroid stimulating-hormone, or T4 concentrations.
• Subject has a planned elective surgery during the study period.
• Subject has a history of hypersensitivity or idiosyncratic reaction to more than 2 drug classes (by chemical classification).
• Subject has abnormal Screening visit laboratory values.
• Subject is using any of the following medications : heparin, ticlopidine, ginko (in subjects taking warfarin), oral steroids (\>/= 7 days per month), chronic use of strong CYP3A4 inhibitors (HIV protease inhibitors, macrolide antibiotics and nefazodone), chronic use of CYP3A4 inducers (carbamazepine, phenytoin, rifampin, and St. John's Wort).

Sponsors & Collaborators

• Bennett, Robert, M.D.: lead
• Merck Sharp & Dohme LLC: collaborator

Study Sites (1)

Oregon Health & Science University

Portland, Oregon, 97239, United States

Location

Related Publications (2)

• Bennett RM, Cook DM, Clark SR, Burckhardt CS, Campbell SM. Hypothalamic-pituitary-insulin-like growth factor-I axis dysfunction in patients with fibromyalgia. J Rheumatol. 1997 Jul;24(7):1384-9.

  PMID: 9228141 BACKGROUND

• Bennett RM, Clark SC, Walczyk J. A randomized, double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia. Am J Med. 1998 Mar;104(3):227-31. doi: 10.1016/s0002-9343(97)00351-3.

  PMID: 9552084 BACKGROUND

MeSH Terms

Conditions

Fibromyalgia

Interventions

ibutamoren mesylate

Condition Hierarchy (Ancestors)

Muscular Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Neuromuscular Diseases; Nervous System Diseases

Study Officials

• Robert Bennett, MD

  Oregon Health and Science University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDIV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor of Medicine OHSU

Study Record Dates

• First Submitted: June 27, 2005
• First Posted: June 28, 2005
• Study Start: July 1, 2005
• Primary Completion: January 1, 2008
• Study Completion: April 1, 2008
• Last Updated: August 6, 2012

Record last verified: 2012-08

Locations

US (1)